
Arthroplasty
TXA effective in reducing blood loss and transfusion in TKA vs. routine hemostasis
This report has been verified
by one or more authors of the
original publication.
Arch Orthop Trauma Surg. 2015 Jul;135(7):1017-25
150 patients undergoing primary total knee arthroplasty (TKA) were randomized to receive 1 g of topical tranexamic acid (TXA), 2 g of intravenous TXA, or routine hemostasis. The purpose of the study was to determine which TXA administration modality more effectively reduced total blood loss 24 post-surgery and the need for subsequent blood transfusions. Findings indicated that although a significant reduction in 24h postoperative blood loss and need for blood transfusion was seen with tranexamic acid administration, no differences were seen between topical and intravenous administration techniques.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.